Tiziana Life Sciences PLC (LON:TILS) insider Gabriele Cerrone acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were bought at an average price of GBX 75 ($0.98) per share, with a total value of £3,750 ($4,900.04).
Gabriele Cerrone also recently made the following trade(s):
- On Friday, May 31st, Gabriele Cerrone acquired 5,000 shares of Tiziana Life Sciences stock. The shares were bought at an average price of GBX 57 ($0.74) per share, with a total value of £2,850 ($3,724.03).
- On Wednesday, May 1st, Gabriele Cerrone acquired 10,000 shares of Tiziana Life Sciences stock. The shares were bought at an average price of GBX 60 ($0.78) per share, with a total value of £6,000 ($7,840.06).
Shares of LON TILS opened at GBX 76.40 ($1.00) on Tuesday. The company has a debt-to-equity ratio of 59.12, a current ratio of 1.08 and a quick ratio of 1.03. The firm has a market cap of $104.26 million and a P/E ratio of -16.26. Tiziana Life Sciences PLC has a 1-year low of GBX 36 ($0.47) and a 1-year high of GBX 148 ($1.93).
TRADEMARK VIOLATION NOTICE: “Tiziana Life Sciences PLC (LON:TILS) Insider Purchases £3,750 in Stock” was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.wkrb13.com/2019/06/11/tiziana-life-sciences-plc-lontils-insider-purchases-3750-in-stock.html.
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
See Also: What is the definition of a trade war?
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.